The U.S. ambulatory infusion centers market was valued at USD 8.9 billion in 2024 and is projected to reach USD 22.5 billion by the end of 2035. The market is expected to grow at a robust CAGR of 8.8% from 2025 to 2035, driven by the rising prevalence of chronic diseases, increasing preference for outpatient care, and advancements in infusion therapy services.

👉 Get sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86733

Market Overview

The U.S. ambulatory infusion centers industry is moving fast as healthcare providers search for effective, patient-friendly alternatives to hospital-based infusion therapy. Ambulatory infusion centers can provide outpatient intravenous treatments, granting patients access to the necessary medications in a comfortable, specialized environment, like in a hospital, without a hospital stay.

They are supported by a growing U.S. ambulatory infusion centers market due to increasingly prevalent biologic therapies with precise administration and monitoring. Ambulatory infusion centers are a lower-cost option than the hospital for patients needing regular infusions and they provide a higher quality of care with most patients receiving the medication and providing a hospital of specialized expertise.

Ambulatory infusion centers are becoming the preferred option for both patients needing the treatment and the healthcare providers, as they are more convenient and accessible alternatives. Technology advancements are also changing the U.S. ambulatory infusion centers market.

Analysts’ Viewpoint on the U.S. Ambulatory Infusion Centers Market

The U.S. ambulatory infusion centers market is expected to grow at a faster pace during the forecast period, mainly due to a greater demand for cost-effective and patient-centered care options. Ambulatory infusion centers service patients in an outpatient setting for intravenous therapies, providing a more convenient service where the patient does not have to be treated in a hospital setting.

The growth of the U.S. ambulatory infusion center sector is primarily due to the increasing incidence of chronic illnesses (e.g. cancer, autoimmune disease, cardiovascular diseases) that require multiple infusions of therapy in a particular time period. Also, the increased availability of biologics and specialty medications has led to more treatment options for patients, and thus the need for an infusion service.

Analysis of Key Players in the U.S. Ambulatory Infusion Centers Market

The competitive landscape is characterized by rapid consolidation as national providers acquire local physician-office-based infusion suites to create standardized, multi-state networks.

Leading companies operating in the U.S. ambulatory infusion centers market include:

• Flexcare Infusion Centers
• Thrivewell
• Hy-Vee Health
• Agile Infusion Services LLC
• Infusion Solutions
• IVXpress, Inc.
• Infusion for Health
• Cedars-Sinai
• Arnot Health
• PharmaScript
• Naval Medical Center Portsmouth
• Valley Health Systems
• Cheyenne Regional Medical Center
• Pacific Medical Centers
• ChristianaCare

These players are focusing on geographic density and payer partnerships to secure exclusive “preferred provider” status, effectively locking in patient volumes for chronic therapy cycles.

Recent Developments in U.S. Ambulatory Infusion Centers Market

• In January 2025, Optum, a subsidiary of UnitedHealth Group and the parent company of the ambulatory surgery center (ASC) chain SCA Health, announced its agreement to acquire FlexCare Infusion. FlexCare Infusion is an ambulatory infusion network with its HQ in Oklahoma City. This acquisition signals Optum’s strategic expansion into the growing market for outpatient infusion services, thereby complementing SCA Health’s existing network of surgical facilities.
• In April 2024, Hy-Vee, Inc. opened its first infusion clinic in West Des Moines, Iowa, offering treatments for chronic conditions. The clinic, staffed by licensed physicians and nurse practitioners, features five group suites and three private rooms.

👉 Discuss Implications for Your Industry Request Sample Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=86733

Key Developments in the U.S. Ambulatory Infusion Centers Market

• Strategic M&A: Consolidation of independent physician-office infusion (OICs) into larger, corporately managed ambulatory platforms.
• Biologic Pipeline Growth: Over 40 new injectable specialty drugs are expected to receive FDA approval by 2027, creating immediate demand for AIC capacity.
• Smart Pump Interoperability: Integration of infusion hardware directly with electronic health records (EHR) to automate billing and reduce clinical errors.
• Patient Experience Focus: Shift toward “spa-like” amenities, including private suites, high-speed Wi-Fi, and personalized nutrition during treatment.
• Virtual Care Coordination: Use of telehealth to manage pre-infusion consultations and post-treatment follow-ups.

Key Player Strategies

🤝 Strategic Payer Alignment

Forming joint ventures with insurance companies to become the “default” site of care for high-cost specialty medications.

🏥 Specialty Diversification

Expanding beyond oncology into high-growth areas like gastroenterology (IBD), neurology (Multiple Sclerosis), and rare orphan diseases.

🤖 AI-Enabled Productivity

Deploying AI to handle complex prior authorizations and benefit navigations, which are currently major bottlenecks in care delivery.

📍 Hyper-Local Expansion

Identifying “care deserts” where patients currently travel over 50 miles for hospital infusions and establishing satellite AICs.

👩‍⚕️ Workforce Retention Programs

Addressing the nurse shortage through premium pay scales and specialized training certifications for infusion-certified registered nurses (CRNI).

Challenges

• Nursing Workforce Shortage: Over 60% of centers report difficulty in recruiting infusion-trained staff.
• Complex Reimbursement Landscape: Navigating “Buy-and-Bill” versus “White Bagging” models remains a significant administrative burden.
• High Real Estate Costs: Securing ADA-compliant, high-visibility clinical space in urban centers.
• Regulatory Scrutiny: Increased federal oversight into private equity-led consolidations in the healthcare space.

Opportunities

💉 Biosimilar Adoption

The entry of lower-cost biosimilars for blockbuster drugs (e.g., Humira, Stelara) is incentivizing payers to shift volume toward AICs.

3️⃣ 340B Program Integration

Collaborations with Federally Qualified Health Centers (FQHCs) to provide on-site infusion for underserved populations.

📈 GLP-1 and Weight Loss Infrastructure

Leveraging AIC infrastructure for the next generation of injectable weight-loss and chronic disease therapies.

🧬 Personalized Medicine

AICs are uniquely positioned to handle “high-touch” precision medicine infusions that require strictly controlled environments.

🏘️ Home-Ambulatory Hybrid Models

Providing patients the choice between home infusion and center-based care under a single provider umbrella.

Market Segmentation

➤ By Therapy Type

• Biologics (Leading segment)
• Chemotherapy
• Immunoglobulin (IVIG)
• Hydration & Anti-infectives
• Iron Therapy & Others

➤ By Application

• Oncology
• Autoimmune Disorders (Rheumatoid Arthritis, Crohn’s)
• Neurological Disorders (MS, CIDP)
• Infectious Diseases
• Other Chronic Conditions

➤ By End User

• Standalone Independent AICs (Fastest-growing)
• Hospital-Affiliated AICs
• Physician-Office Infusion Centers (OIC)

Conclusion

The U.S. Ambulatory Infusion Centers market is positioned for exceptional growth through 2035. As the “value-based care” movement matures, the shift toward these high-efficiency, patient-centric facilities will become permanent. AICs are no longer just a “lower-cost alternative” but are becoming the primary hub for the delivery of the world’s most advanced specialty pharmaceuticals.

With a projected market value exceeding US$ 22 Bn, the next decade will be defined by technological integration and the optimization of the patient journey from diagnosis to long-term infusion management.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=86733&ltype=S

FAQs

• How big was the U.S. ambulatory infusion centers market in 2024?

The U.S ambulatory infusion centers market was valued at US$ 8.9 Bn in 2024.

• How big will the U.S. ambulatory infusion centers business be in 2035?

The U.S ambulatory infusion centers market is projected to cross US$ 22.5 Bn by the end of 2035.

• What are the factors driving the U.S. ambulatory infusion centers market?

Rising prevalence of chronic diseases and cost efficiency and favorable reimbursement models.

• What will be the CAGR of the U.S. ambulatory infusion centers industry during the forecast period?

The CAGR is anticipated to be 8.8% from 2025 to 2035.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com